Healthcare corporations are filling a void left by retreating venture capital firms in their sector.

Edited highlights from last month's Keynote Healthcare Q&A at the Global Corporate Venturing Symposium 2012 with Merck's William Taranto and Cleveland Clinic's Tom Thornton.

Venture firm Boston Millennia Partners's Patrick Fortune joins Cleveland Clinic Innovations.

Kaiser Permanente Ventures is joined leading the series D round by venture firm Redmile Group.

Healthcare company Forest Laboratories provides antibiotic drug company Nabriva Therapeutics with $25m for a new drug, and wins exclusive right to acquire the company.

Johnson & Johnson Development Corporation and Astellas Venture Management back the drug developer alongside venture firms New Enterprise Associates, Hatteras Venture Partners and Fletcher Spaght Ventures.

Corporate-backed German state venture fund backs the cell therapy company, as well as Algiax Pharmaceuticals, a healthcare company.

Workers at Germany-based pharmaceutical company Merck Serono are reportedly campaigning for it to do more venture capital, as part of a protest about the shut down of its Swiss base.

The company which selects drugs for neuropsychiatric patients is backed again by healthcare company Mayo Clinic and hospital Cincinnati Children's Hospital, which is based on technology from the two investors.